Johnson & Johnson Lyell Immunopharma, Inc. Transaction History
Johnson & Johnson
- $301 Million
- Q1 2025
A detailed history of Johnson & Johnson transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Johnson & Johnson holds 823,317 shares of LYEL stock, worth $8.37 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
823,317
Previous 823,317
-0.0%
Holding current value
$8.37 Million
Previous $526,000
15.59%
% of portfolio
0.15%
Previous 0.18%
Shares
1 transactions
Others Institutions Holding LYEL
# of Institutions
117Shares Held
175MCall Options Held
2.9KPut Options Held
6K-
Mwg Management Ltd. Washington, DC20.2MShares$205 Million18.54% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA16MShares$163 Million9.84% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$154 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$154 Million9.84% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$137 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $2.52B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...